| scholarly article | Q13442814 |
| P2093 | author name string | H Ozaki | |
| D J Zack | |||
| T Tobe | |||
| N Okamoto | |||
| P A Campochiaro | |||
| S F Hackett | |||
| M A Vinores | |||
| W LaRochelle | |||
| P2860 | cites work | Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction | Q25938986 |
| Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation | Q28510000 | ||
| Vascular endothelial growth factor is a secreted angiogenic mitogen | Q28646475 | ||
| Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis | Q29617644 | ||
| The role of retinal pigment epithelium in the involution of subretinal neovascularization. | Q31145223 | ||
| Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins | Q33775844 | ||
| Experimental retinal branch vein occlusion in miniature pigs induces local tissue hypoxia and vasoproliferative microangiopathy | Q34205247 | ||
| Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. | Q34292373 | ||
| Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders | Q34292807 | ||
| Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy | Q34324536 | ||
| Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate | Q34369354 | ||
| Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate | Q34387729 | ||
| Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate | Q34409210 | ||
| Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis | Q34578752 | ||
| Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization | Q34749337 | ||
| Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment | Q35782383 | ||
| Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells | Q36217700 | ||
| Experimental choroidal neovascularization in the rat | Q36676668 | ||
| Regression of Experimental Iris Neovascularization with Systemic Alpha-interferon | Q36695100 | ||
| Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression | Q37350460 | ||
| Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy | Q37607034 | ||
| Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy | Q38302775 | ||
| Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. | Q44393459 | ||
| Overexpression of vascular endothelial growth factor in the avian embryo induces hypervascularization and increased vascular permeability without alterations of embryonic pattern formation | Q44770040 | ||
| Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo | Q45879123 | ||
| Retinal vascularization in health and disease: Proctor Award Lecture of the Association for Research in Ophthalmology. | Q48430703 | ||
| Pericyte coverage of retinal and cerebral capillaries. | Q48957274 | ||
| Retinal degeneration in transgenic mice with photoreceptor-specific expression of a dominant-negative fibroblast growth factor receptor. | Q52520863 | ||
| Unusual topography of bovine rhodopsin promoter-lacZ fusion gene expression in transgenic mouse retinas. | Q54701113 | ||
| Astrocytes induce blood–brain barrier properties in endothelial cells | Q57318253 | ||
| Experimental retinal neovascularization induced by intravitreal tumors | Q67582466 | ||
| Blindness caused by diabetic retinopathy | Q69781866 | ||
| The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization | Q70549804 | ||
| Variable oxygen exposure causes preretinal neovascularization in the newborn rat | Q70600600 | ||
| Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity | Q71007156 | ||
| Localization of vascular endothelial growth factor in human retina and choroid | Q71226459 | ||
| Injury-induced upregulation of bFGF and CNTF mRNAS in the rat retina | Q71511587 | ||
| Oxygen-induced retinopathy in the mouse | Q71608431 | ||
| Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases | Q71697254 | ||
| Experimental Rat Model of Neovascularization Arising from the Optic Disk | Q72088591 | ||
| Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells | Q72514058 | ||
| Retinal Neovascularization After Intravitreal Fibroblast Injection | Q72640493 | ||
| Ocular neovascularization with retinal vascular occlusion. I. Association with experimental retinal vein occlusion | Q72661919 | ||
| Current concepts of the effect of oxygen on the developing retina | Q72720095 | ||
| Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates | Q73519344 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| neovascularization | Q1281049 | ||
| P304 | page(s) | 281-291 | |
| P577 | publication date | 1997-07-01 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization | |
| P478 | volume | 151 |
| Q38663964 | A Proinflammatory Function of Toll-Like Receptor 2 in the Retinal Pigment Epithelium as a Novel Target for Reducing Choroidal Neovascularization in Age-Related Macular Degeneration. |
| Q34007035 | A potential therapeutic strategy for inhibition of ocular neovascularization with a new endogenous protein: rhEDI-8t |
| Q47225954 | AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration. |
| Q58719110 | ATN-161 as an Integrin α5β1 Antagonist Depresses Ocular Neovascularization by Promoting New Vascular Endothelial Cell Apoptosis |
| Q42125573 | Ablation of 4E-BP1/2 prevents hyperglycemia-mediated induction of VEGF expression in the rodent retina and in Muller cells in culture |
| Q30523799 | Abnormal vascularization in mouse retina with dysregulated retinal cholesterol homeostasis |
| Q35126780 | Age-Related Macular Degeneration: Etiology, Pathogenesis, and Therapeutic Strategies |
| Q34407622 | Age-related macular degeneration: genetic and environmental factors of disease |
| Q37734451 | Agents that bind annexin A2 suppress ocular neovascularization |
| Q36804949 | An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization |
| Q33943213 | An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration |
| Q36222187 | Angiographic results of retinal-retinal anastomosis and retinal-choroidal anastomosis after treatments in eyes with retinal angiomatous proliferation |
| Q41504603 | Animal Models of Diabetic Retinopathy |
| Q33582933 | Animal models of choroidal and retinal neovascularization |
| Q39455385 | Animal models of ocular angiogenesis: from development to pathologies |
| Q35024891 | Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A |
| Q35753400 | Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization |
| Q28743307 | Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye |
| Q35745444 | Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization |
| Q43755773 | Blood-retinal barrier breakdown in experimental coronavirus retinopathy: association with viral antigen, inflammation, and VEGF in sensitive and resistant strains |
| Q30491774 | CLINICAL FEATURES OF TREATED AND UNTREATED TYPE 1 IDIOPATHIC MACULAR TELANGIECTASIA WITHOUT THE OCCURRENCE OF SECONDARY CHOROIDAL NEOVASCULARIZATION FOLLOWED FOR 2 YEARS IN JAPANESE PATIENTS. |
| Q38767261 | Cell-based therapeutic strategies for replacement and preservation in retinal degenerative diseases |
| Q33969496 | Cellular mechanisms of blood-retinal barrier dysfunction in macular edema |
| Q34254645 | Characterization of a Mouse Model of Hyperglycemia and Retinal Neovascularization |
| Q27312714 | Characterization of a spontaneous retinal neovascular mouse model |
| Q35658254 | Co-culture of Retinal and Endothelial Cells Results in the Modulation of Genes Critical to Retinal Neovascularization |
| Q33293815 | Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. |
| Q31138791 | Current and future treatment options for nonexudative and exudative age-related macular degeneration. |
| Q34521256 | Deficiency of neuropilin 2 suppresses VEGF-induced retinal neovascularization |
| Q37703235 | Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes |
| Q33292156 | Development of a new mouse model of branch retinal vein occlusion and retinal neovascularization |
| Q33868764 | Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization |
| Q30631779 | Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor |
| Q30490563 | EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE. |
| Q45269945 | Ectopic norrin induces growth of ocular capillaries and restores normal retinal angiogenesis in Norrie disease mutant mice. |
| Q42113345 | Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor |
| Q35765120 | Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. |
| Q37482353 | FAK and p38-MAP kinase-dependent activation of apoptosis and caspase-3 in retinal endothelial cells by alpha1(IV)NC1 |
| Q54977469 | Flt3 Regulation in the Mononuclear Phagocyte System Promotes Ocular Neovascularization. |
| Q46298201 | Fluorescein angiography, optical coherence tomography, and histopathologic findings in a VEGF(165) animal model of retinal angiogenesis |
| Q28344709 | Gene transfer by viral vectors into blood vessels in a rat model of retinopathy of prematurity |
| Q51022833 | Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degeneration. |
| Q43007038 | Generation of transgenic mice with mild and severe retinal neovascularisation |
| Q34775400 | HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin |
| Q91658835 | Hepatocyte growth factor is upregulated in ischemic retina and contributes to retinal vascular leakage and neovascularization |
| Q33593430 | High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis |
| Q40753351 | Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. |
| Q35747297 | Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment |
| Q51744772 | Inhibition of integrin α5β1 ameliorates VEGF-induced retinal neovascularization and leakage by suppressing NLRP3 inflammasome signaling in a mouse model. |
| Q38809713 | Interleukin-17A neutralization alleviated ocular neovascularization by promoting M2 and mitigating M1 macrophage polarization. |
| Q35191520 | Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF. |
| Q43202451 | Intra-ocular expression of vascular endothelial growth factor (VEGF) and pigment epithelial-derived factor (PEDF) in a case of Eales' disease by immunohistochemical analysis: a case report |
| Q28359761 | Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium |
| Q33873875 | Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series. |
| Q37864178 | Intravitreal bevacizumab versus photodynamic therapy for myopic choroidal neovascularization in a North-African population. |
| Q45224240 | Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice |
| Q62066203 | Long-term global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model |
| Q33899013 | Macular oedema: the role of soluble mediators |
| Q34316044 | Macular telangiectasia type 2. |
| Q30249206 | Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy |
| Q36822355 | Microphthalmia, persistent hyperplastic hyaloid vasculature and lens anomalies following overexpression of VEGF-A188 from the alphaA-crystallin promoter. |
| Q36296789 | Molecular pathogenesis of retinal and choroidal vascular diseases |
| Q43008006 | Mouse genetic corneal disease resulting from transgenic insertional mutagenesis |
| Q52568540 | Mousetap, a Novel Technique to Collect Uncontaminated Vitreous or Aqueous and Expand Usefulness of Mouse Models. |
| Q41975515 | Novel endogenous glycan therapy for retinal diseases: safety, in vitro stability, ocular pharmacokinetic modeling, and biodistribution. |
| Q38074872 | Ocular neovascularization |
| Q42850925 | Ocular neovascularization: clarifying complex interactions |
| Q38018840 | Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma |
| Q34185266 | Over-expression of BMP4 inhibits experimental choroidal neovascularization by modulating VEGF and MMP-9. |
| Q33808055 | Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization |
| Q40870038 | Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization |
| Q34000654 | Oxidative stress promotes ocular neovascularization. |
| Q41091625 | Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab |
| Q35923424 | Phenotypic and functional characterization of Bst+/- mouse retina. |
| Q36942442 | Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. |
| Q35829410 | Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment |
| Q37064822 | Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration |
| Q35745360 | Platelet-derived growth factor-A-induced retinal gliosis protects against ischemic retinopathy |
| Q40937602 | Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation |
| Q37428029 | Preeclampsia and small-for-gestational age are associated with decreased concentrations of a factor involved in angiogenesis: soluble Tie-2. |
| Q34477473 | Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor |
| Q41633916 | Profound effects on vascular development caused by perturbations during organogenesis |
| Q37734454 | Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells |
| Q24798892 | Rapid degradation of dominant-negative Rab27 proteins in vivo precludes their use in transgenic mouse models. |
| Q90716279 | Rb1/Rbl1/Vhl loss induces mouse subretinal angiomatous proliferation and hemangioblastoma |
| Q35055667 | Regulated in development and DNA damage 1 is necessary for hyperglycemia-induced vascular endothelial growth factor expression in the retina of diabetic rodents |
| Q35216918 | Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation. |
| Q64937118 | Retinal Vasculature in Development and Diseases. |
| Q37100773 | Retinal angiomatous proliferation and intravitreal bevacizumab injection |
| Q74649816 | Retinopathy of prematurity: recent advances in our understanding |
| Q34659611 | Retinopathy of prematurity: recent advances in our understanding. |
| Q35210888 | Retracted: Nuclear Factor Kappa-B Signaling Is Integral to Ocular Neovascularization in Ischemia-Independent Microenvironment |
| Q42367664 | Reversible retinal vessel closure from VEGF-induced leukocyte plugging |
| Q34039271 | Role of connective tissue growth factor in the retinal vasculature during development and ischemia |
| Q33267276 | Short and long-term effects of hVEGF-A(165) in Cre-activated transgenic mice |
| Q88518534 | Submacular hemorrhage and grape-like polyp clusters: factors associated with reactivation of the lesion in polypoidal choroidal vasculopathy |
| Q30560557 | Sustained delivery of a HIF-1 antagonist for ocular neovascularization |
| Q89531841 | Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles |
| Q31977156 | Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model |
| Q51735584 | Targeting Hif1a rescues cone degeneration and prevents subretinal neovascularization in a model of chronic hypoxia. |
| Q38990050 | Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema |
| Q34311551 | Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature |
| Q35050974 | The bst locus on mouse chromosome 16 is associated with age-related subretinal neovascularization |
| Q30495106 | The mouse retina as an angiogenesis model |
| Q24605541 | The orphan nuclear receptor COUP-TFII is required for angiogenesis and heart development |
| Q24532130 | The potential role of amyloid beta in the pathogenesis of age-related macular degeneration |
| Q36573796 | Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit |
| Q44623709 | Transforming growth factor‐β induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: Involvement of mitogen‐activated protein kinases |
| Q42838776 | Transgenic mice model of ocular neovascularization driven by vascular endothelial growth factor (VEGF) overexpression |
| Q86551292 | Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation |
| Q49334226 | Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage |
| Q36051041 | Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals |
| Q38884418 | VEGF induces neuroglial differentiation in bone marrow-derived stem cells and promotes microglia conversion following mobilization with GM-CSF. |
| Q55331083 | VEGF/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models. |
| Q35197956 | Vascular cell-adhesion molecule-1 plays a central role in the proangiogenic effects of oxidative stress |
| Q35810089 | Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). |
| Q42775475 | Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. |
| Q36929380 | Vascular endothelial growth factor in eye disease |
| Q41843418 | Zeaxanthin inhibits hypoxia-induced VEGF secretion by RPE cells through decreased protein levels of hypoxia-inducible factors-1α. |
Search more.